Redeye comments on Magle’s strategic pivot toward profitability, operational discipline, and sustain...
Redeye comments on the news that Egetis has completed its rolling NDA submission for Emcitate in the...
Suominen Q4 comparable EBITDA of EUR 1.9m came 60% below Vara Research consensus expectations.
Redeye provides its initial take on Indutrade’s Q4 2025 report, which missed on earnings, mainly due...
Redeye comments on q.beyond’s preliminary Q4 figures, showing stronger EBITDA than expected.
VNV reported a Q4 NAV per share which is down 8% q/q in SEK terms and the company ended the year wit...
Physitrack released preliminary Q4 2025 figures this morning, which were broadly in line with our ex...
We raise adjusted EBITA by 2% for 2026E-27E, following the stronger-than-expected profitability in Q...
* 27% y-o-y organic sales growth in Q4'25e * No change to financial targets expected Q4'25 results d...
Vi inleder bevakning på Dellia Group, ett snabbväxande nordiskt konsumentvarubolag verksamt inom tor...
Redeye returns with a more in-depth take on Xvivo’s Q4 report.
Redeye updates its estimates and valuation after VEF’s Q4 2025 report.
We expect CapMan’s Q4 fee business to have developed steadily from Q3 with some seasonally increased...
Alcadon continues to prioritise profitability and capital efficiency, underscored by its decision to...
* Strong orders should continue to convert into sales growth (17%) * Enedo stabilising as comps ease...
Avtech released preliminary figures for Q4 2025 which fell short of Redeye expectations on both sale...
* Impairments of ~SEK 240m in Q4 * Preliminary Q4 EBIT of ~SEK -315m (vs.
Det tredje kvartalet överträffade våra prognoser för både nettoomsättning och ebita, drivet av en fo...
We expect a strong positive share price reaction today of c15%, given the beat on sales, profitabili...
DT reports Q4 results on Feb 5. Last year was challenging, but now Q1’26 should see double-digit gro...
